Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.

Saved in:
Bibliographic Details
Title: Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.
Authors: Derer S; Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, Christian-Albrechts-University, Kiel, Germany., Berger S, Schlaeth M, Schneider-Merck T, Klausz K, Lohse S, Overdijk MB, Dechant M, Kellner C, Nagelmeier I, Scheel AH, Lammerts van Bueren JJ, van de Winkel JG, Parren PW, Peipp M, Valerius T
Source: Neoplasia (New York, N.Y.) [Neoplasia] 2012 Mar; Vol. 14 (3), pp. 190-205.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100886622 Publication Model: Print Cited Medium: Internet ISSN: 1476-5586 (Electronic) Linking ISSN: 14765586 NLM ISO Abbreviation: Neoplasia Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5586
DOI:10.1593/neo.111636